<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(2)</volume><submitter>Ferreira VH</submitter><pubmed_abstract>Mutations in the spike protein of SARS-CoV-2 have allowed Omicron subvariants to escape neutralizing antibodies. The degree to which this occurs in transplant recipients is poorly understood. We measured BA.4/5 cross-neutralizing responses in 75 mostly vaccinated transplant recipients who recovered from BA.1 infection. Sera were collected at 1 and 6 months post-BA.1 infection, and a lentivirus pseudovirus neutralization assay was performed using spike constructs corresponding to BA.1 and BA.4/5. Uninfected immunized transplant recipients and health care worker controls were used for comparison. Following BA.1 infection, the proportion of transplant recipients with neutralizing antibody responses was 88.0% (66/75) against BA.1 and 69.3% (52/75) against BA.4/5 (P = .005). The neutralization </pubmed_abstract><journal>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</journal><pagination>278-283</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9835003</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients.</pubmed_title><pmcid>PMC9835003</pmcid><pubmed_authors>Kumar D</pubmed_authors><pubmed_authors>Ierullo M</pubmed_authors><pubmed_authors>Kurtesi A</pubmed_authors><pubmed_authors>Ferreira VH</pubmed_authors><pubmed_authors>Humar A</pubmed_authors><pubmed_authors>Solera JT</pubmed_authors><pubmed_authors>Hu Q</pubmed_authors><pubmed_authors>Gingras AC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients.</name><description>Mutations in the spike protein of SARS-CoV-2 have allowed Omicron subvariants to escape neutralizing antibodies. The degree to which this occurs in transplant recipients is poorly understood. We measured BA.4/5 cross-neutralizing responses in 75 mostly vaccinated transplant recipients who recovered from BA.1 infection. Sera were collected at 1 and 6 months post-BA.1 infection, and a lentivirus pseudovirus neutralization assay was performed using spike constructs corresponding to BA.1 and BA.4/5. Uninfected immunized transplant recipients and health care worker controls were used for comparison. Following BA.1 infection, the proportion of transplant recipients with neutralizing antibody responses was 88.0% (66/75) against BA.1 and 69.3% (52/75) against BA.4/5 (P = .005). The neutralization </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-05T13:22:03.385Z</modification><creation>2025-02-19T01:27:17.07Z</creation></dates><accession>S-EPMC9835003</accession><cross_references><pubmed>36744606</pubmed><doi>10.1016/j.ajt.2022.10.004</doi></cross_references></HashMap>